Amicus Therapeutics Enters License Agreement With Teva, Resolving Galafold Patent Litigation; No Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics has entered a license agreement with Teva, resolving their patent litigation over GALAFOLD. Teva can market a generic version in the US starting January 30, 2037, pending FDA approval. The litigation against Aurobindo continues, while Lupin's case is stayed.
October 17, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics resolves patent litigation with Teva, allowing Teva to market a generic GALAFOLD in the US from 2037, pending FDA approval.
The resolution of the patent litigation with Teva removes a significant legal hurdle for Amicus, potentially stabilizing its market position for GALAFOLD until 2037. This is positive for Amicus as it secures its market exclusivity for a longer period.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Teva Pharmaceuticals has secured a license to market a generic version of GALAFOLD in the US starting January 30, 2037, pending FDA approval.
Teva's agreement with Amicus allows it to enter the market with a generic version of GALAFOLD in 2037, which could be beneficial for its long-term strategy in the US market.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80